102 related articles for article (PubMed ID: 25001659)
21. A retrospective observational study of primary cutaneous malignant melanoma patients treated with excision only compared with excision biopsy followed by wider local excision.
McKenna DB; Lee RJ; Prescott RJ; Doherty VR
Br J Dermatol; 2004 Mar; 150(3):523-30. PubMed ID: 15030337
[TBL] [Abstract][Full Text] [Related]
22. The effect of tamoxifen and cisplatin on the disease-free and overall survival of patients with high risk malignant melanoma.
McClay EF; McClay ME; Monroe L; Baron PL; Cole DJ; O'Brien PH; Metcalf JS; Maize JC
Br J Cancer; 2000 Jul; 83(1):16-21. PubMed ID: 10883662
[TBL] [Abstract][Full Text] [Related]
23. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas.
Cherpelis BS; Haddad F; Messina J; Cantor AB; Fitzmorris K; Reintgen DS; Fenske NA; Glass LF
J Am Acad Dermatol; 2001 May; 44(5):762-6. PubMed ID: 11312421
[TBL] [Abstract][Full Text] [Related]
24. A randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients.
Mao L; Si L; Chi Z; Cui C; Sheng X; Li S; Tang B; Guo J
Eur J Cancer; 2011 Jul; 47(10):1498-503. PubMed ID: 21493058
[TBL] [Abstract][Full Text] [Related]
25. Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma.
Brandberg Y; Johansson H; Aamdal S; Bastholt L; Hernberg M; Stierner U; von der Maase H; Hansson J;
Acta Oncol; 2013 Aug; 52(6):1086-93. PubMed ID: 23621752
[TBL] [Abstract][Full Text] [Related]
26. Is there a benefit to sentinel lymph node biopsy in patients with T4 melanoma?
Gajdos C; Griffith KA; Wong SL; Johnson TM; Chang AE; Cimmino VM; Lowe L; Bradford CR; Rees RS; Sabel MS
Cancer; 2009 Dec; 115(24):5752-60. PubMed ID: 19827151
[TBL] [Abstract][Full Text] [Related]
27. Long-term outcome of postoperative interferon-alpha adjuvant therapy for non-metastatic renal cell carcinoma.
Gotoh A; Shirakawa T; Hinata N; Wada Y; Hara I; Fujisawa M; Kawabata G; Okada H; Arakawa S; Kamidono S
Int J Urol; 2004 May; 11(5):257-63. PubMed ID: 15147539
[TBL] [Abstract][Full Text] [Related]
28. Diversity of stage III melanoma in the era of sentinel lymph node biopsy.
Egger ME; Callender GG; McMasters KM; Ross MI; Martin RC; Edwards MJ; Urist MM; Noyes RD; Sussman JJ; Reintgen DS; Stromberg AJ; Scoggins CR
Ann Surg Oncol; 2013 Mar; 20(3):956-63. PubMed ID: 23064795
[TBL] [Abstract][Full Text] [Related]
29. Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG "GERMELATOX survey") versus melanoma recurrence to quantify patients' relative values for adjuvant therapy.
Kaehler KC; Blome C; Forschner A; Gutzmer R; Haalck T; Heinzerling L; Kornek T; Livingstone E; Loquai C; Maul LV; Lang BM; Schadendorf D; Stade B; Terheyden P; Utikal J; Wagner T; Hauschild A; Garbe C; Augustin M
Medicine (Baltimore); 2016 Nov; 95(46):e5375. PubMed ID: 27861370
[TBL] [Abstract][Full Text] [Related]
30. High positive sentinel node identification rate by EORTC melanoma group protocol. Prognostic indicators of metastatic patterns after sentinel node biopsy in melanoma.
van Akkooi AC; de Wilt JH; Verhoef C; Graveland WJ; van Geel AN; Kliffen M; Eggermont AM
Eur J Cancer; 2006 Feb; 42(3):372-80. PubMed ID: 16403622
[TBL] [Abstract][Full Text] [Related]
31. Clinical and pathologic factors associated with distant metastasis and survival in patients with thin primary cutaneous melanoma.
Murali R; Haydu LE; Long GV; Quinn MJ; Saw RP; Shannon K; Spillane AJ; Stretch JR; Kefford RF; Thompson JF; Scolyer RA
Ann Surg Oncol; 2012 Jun; 19(6):1782-9. PubMed ID: 22350600
[TBL] [Abstract][Full Text] [Related]
32. Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial.
Stadler R; Luger T; Bieber T; Köhler U; Linse R; Technau K; Schubert R; Schroth K; Vakilzadeh F; Volkenandt M; Gollnick H; Von Eick H; Thoren F; Strannegård O
Acta Oncol; 2006; 45(4):389-99. PubMed ID: 16760174
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of sentinel node biopsy in 327 prospective melanoma patients from a single institution.
Roulin D; Matter M; Bady P; Liénard D; Gugerli O; Boubaker A; Bron L; Lejeune FJ
Eur J Surg Oncol; 2008 Jun; 34(6):673-9. PubMed ID: 17825518
[TBL] [Abstract][Full Text] [Related]
34. Is head and neck melanoma different from trunk and extremity melanomas with respect to sentinel lymph node status and clinical outcome?
Fadaki N; Li R; Parrett B; Sanders G; Thummala S; Martineau L; Cardona-Huerta S; Miranda S; Cheng ST; Miller JR; Singer M; Cleaver JE; Kashani-Sabet M; Leong SP
Ann Surg Oncol; 2013 Sep; 20(9):3089-97. PubMed ID: 23649930
[TBL] [Abstract][Full Text] [Related]
35. White blood cell count: a prognostic factor and possible subset indicator of optimal treatment with low-dose adjuvant interferon in primary melanoma.
de La Salmonière P; Grob JJ; Dreno B; Delaunay M; Chastang C
Clin Cancer Res; 2000 Dec; 6(12):4713-8. PubMed ID: 11156224
[TBL] [Abstract][Full Text] [Related]
36. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials.
Lens MB; Dawes M
J Clin Oncol; 2002 Apr; 20(7):1818-25. PubMed ID: 11919239
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant high-dose interferon-alpha therapy for high-risk melanoma.
Kirkwood JM; Tarhini AA
Forum (Genova); 2003; 13(2):127-40; quiz 187-8. PubMed ID: 14732880
[TBL] [Abstract][Full Text] [Related]
38. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival.
Bedikian AY; Johnson MM; Warneke CL; McIntyre S; Papadopoulos N; Hwu WJ; Kim K; Hwu P
J Immunotoxicol; 2008 Apr; 5(2):201-7. PubMed ID: 18569391
[TBL] [Abstract][Full Text] [Related]
39. Relevance of multiple basin drainage and primary histologic regression in prognosis of trunk melanoma patients with negative sentinel lymph nodes.
Ribero S; Quaglino P; Osella-Abate S; Sanlorenzo M; Senetta R; Macrì L; Savoia P; Macripò G; Sapino A; Bernengo MG
J Eur Acad Dermatol Venereol; 2013 Sep; 27(9):1132-7. PubMed ID: 22998598
[TBL] [Abstract][Full Text] [Related]
40. Prognostic implications of anatomic location of primary cutaneous melanoma of 1 mm or thicker.
Callender GG; Egger ME; Burton AL; Scoggins CR; Ross MI; Stromberg AJ; Hagendoorn L; Martin RC; McMasters KM
Am J Surg; 2011 Dec; 202(6):659-64; discussion 664-5. PubMed ID: 22137134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
